Timing clarification: MetLife is scheduled to release results today, Wednesday, August 5, 2026, after the market closes. The earnings call is tomorrow, Thursday, August 6, from 9–10 a.m. ET. (investor.metlife.com)
MetLife enters earnings with strong operating momentum but a substantially higher stock price and one important headwind already disclosed: variable investment income will fall sharply from the exceptional first quarter.
The central question is therefore not simply whether MET beats the EPS consensus. Investors will want evidence that underlying earnings—mortality, business growth, recurring investment spreads, expenses and capital returns—can offset lower variable investment income and support management’s longer-term “New Frontier” targets.
My base expectation is:
Third-party consensus estimates vary, with adjusted EPS forecasts around $2.30–$2.37. Revenue estimates are less useful for an insurer because pension-risk-transfer activity, investment accounting and other items can create large quarterly swings without a corresponding change in underlying profitability. (tipranks.com)
| Metric | Reference point |
|---|---|
| 2Q26 adjusted EPS consensus | Approximately $2.30–$2.37 |
| 1Q26 adjusted EPS | $2.42 |
| 2Q25 adjusted EPS | $2.02 |
| 1Q26 adjusted earnings | $1.59 billion |
| 1Q26 adjusted ROE | 17.0% |
| 1Q26 direct expense ratio | 11.9% |
| 2026 direct expense-ratio target | 12.1% |
MetLife’s first quarter was unusually strong: adjusted EPS rose 23%, adjusted premiums, fees and other revenues excluding pension-risk transfers rose 10%, and every operating segment generated year-over-year earnings growth. (metlife.com)
MetLife has preannounced 2Q variable investment income of $220 million–$270 million pretax, versus:
Thus, VII should improve year over year but decline by roughly $250 million–$300 million sequentially. At the midpoint, that is an estimated $0.33 per-share sequential headwind, assuming a 21% tax rate and approximately 650 million diluted shares. (sec.gov)
At the $245 million midpoint, first-half VII would total approximately $763 million. MetLife would then need about $837 million in the second half, or roughly $419 million per quarter, to reach its full-year assumption.
That requirement is meaningful but achievable. At a June investor conference, CFO John McCallion said the weaker Q2 setup could be followed by a stronger Q3, citing improved markets, technology valuations, IPO activity and MetLife’s venture-capital exposure.
What matters:
A result at the low end is already partly telegraphed. The larger risk would be management sounding less confident about the second-half recovery.
Group Benefits was one of the strongest features of Q1:
Management attributed the life result to favorable working-age mortality, a light flu season, approximately two points of favorable prior-period development and modestly favorable severity. At the June investor conference, the CFO indicated that favorable mortality would probably continue through the year.
The offset is non-medical health. Its benefit ratio was 75.8% in Q1, above the 70%–75% target range, reflecting:
Management previously expected dental and paid-leave pressure to moderate principally in the second half. That means Q2 could remain mixed even if life mortality stays favorable.
Key questions:
A strong Group Benefits quarter driven by both life and improving non-medical health would be more valuable than an EPS beat primarily driven by reserve development.
Retirement and Income Solutions produced $451 million of adjusted earnings in Q1, although the quarter benefited from strong VII and a large structured-settlement reserve release. Management maintained its $1.6 billion–$1.8 billion full-year adjusted-earnings outlook for the segment.
Core investment spread excluding VII was 95 basis points in Q1. Management subsequently said it expected spreads to remain near that level—perhaps moving by only one or two basis points—until the yield curve steepens.
Investors should focus on:
Q1 revenue excluding pension-risk transfers rose 58%, illustrating strong underlying activity, but RIS earnings are unlikely to repeat Q1’s combination of VII and reserve benefits.
Asia delivered $487 million of adjusted earnings in Q1, up 31%, with constant-currency sales up 22%. Japan sales rose 26%, while Korea rose 44%.
Management warned that year-over-year growth would moderate because comparisons become more difficult, but it remained constructive on product demand and distribution. Watch:
Management said in Q1 that the Japanese industry matter had not affected MetLife’s sales or financial results.
Latin America’s underlying growth was stronger than its reported Q1 earnings suggested, as Mexico’s VAT change and other tax items reduced constant-currency earnings. The CFO said in June that the company’s path toward approximately $1 billion of annual Latin American earnings was realistic for 2026.
EMEA should remain a smaller but dependable contributor. Management has described its recent growth as durable, although Q1’s $110 million result was above the normal quarterly earnings range it previously discussed.
The first fully integrated quarter following the PineBridge acquisition produced:
Management described the outflows as a combination of expected post-closing activity, market depreciation and normal client-allocation changes. It also said flows stabilized late in Q1 and that the pipeline was constructive.
For Q2, investors should look for:
MIM is currently a modest earnings contributor, but it is supposed to become MetLife’s fastest-growing segment. Continued outflows would weaken that strategic narrative even if consolidated EPS beats.
MetLife’s Q1 direct expense ratio of 11.9% was better than its 12.1% full-year target despite absorbing PineBridge’s structurally higher expense base. Continued performance near or below 12.1% would reinforce the argument that technology investments and revenue growth are producing operating leverage.
Capital was also strong entering Q2:
The share count remains a meaningful EPS tailwind. Q1 diluted shares fell about 5% year over year, allowing EPS to grow faster than aggregate earnings.
However, MET closed at approximately $96.15 on August 4, up around 22% from year-end and nearly 20% since the Q1 release. The stock now trades near 9.7 times a third-party 2026 adjusted-EPS consensus of $9.91 and about 1.67 times Q1 adjusted book value. The valuation is not demanding in absolute terms, but the stock is no longer entering earnings from a depressed level. (stockanalysis.com)
The quarter should show solid year-over-year EPS growth but a sequential decline from an unusually strong Q1. Lower variable investment income is well understood; the report’s real information content will be whether MetLife’s recurring businesses can absorb that decline.
The most important indicators are:
Given the stock’s strong run, an ordinary EPS beat may not be enough. The most constructive result would pair a beat with clean underwriting, stable MIM flows and clear evidence that the lower Q2 VII result is a timing issue rather than a reduction in MetLife’s normalized earnings power.